Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2008 1
2009 3
2010 3
2011 2
2014 3
2015 6
2016 2
2017 2
2018 1
2019 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Syrigou E. Syrigou E. Pediatr Allergy Immunol. 2015 Aug;26(5):485-6. doi: 10.1111/pai.12412. Pediatr Allergy Immunol. 2015. PMID: 26033775 No abstract available.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
Stefanou MI, Palaiodimou L, Theodorou A, Christodoulou MV, Tzartos JS, Tzanetakos D, Kitsos D, Chondrogianni M, Zouvelou V, Dardiotis E, Tzavellas E, Syrigou E, Benetou V, Paraskevas GP, Tsiodras S, Tsivgoulis G, Giannopoulos S. Stefanou MI, et al. Among authors: syrigou e. Mult Scler. 2023 Apr;29(4-5):585-594. doi: 10.1177/13524585221150881. Epub 2023 Feb 1. Mult Scler. 2023. PMID: 36722184 Free PMC article.
Acute hypersensitivity reactions to chemotherapy agents: an overview.
Syrigou E, Triantafyllou O, Makrilia N, Kaklamanos I, Kotanidou A, Manolopoulos L, Syrigos K. Syrigou E, et al. Inflamm Allergy Drug Targets. 2010 Jul;9(3):206-13. doi: 10.2174/187152810792231887. Inflamm Allergy Drug Targets. 2010. PMID: 20632960 Review.
Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer.
Trontzas IP, Vathiotis I, Economidou C, Petridou I, Gomatou G, Grammoustianou M, Tsamis I, Syrigos N, Anagnostakis M, Fyta E, Sakka V, Poulakou G, Kotteas EA, Syrigou E. Trontzas IP, et al. Among authors: syrigou e. Vaccines (Basel). 2022 Apr 15;10(4):618. doi: 10.3390/vaccines10040618. Vaccines (Basel). 2022. PMID: 35455367 Free PMC article.
Anaphylaxis during rapid oral desensitization to rifampicin.
Syrigou E, Grapsa D, Nanou E, Zande M, Vassias A, Gkiozos I, Syrigos K. Syrigou E, et al. J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):173-4. doi: 10.1016/j.jaip.2015.09.009. Epub 2015 Oct 24. J Allergy Clin Immunol Pract. 2016. PMID: 26603634 No abstract available.
28 results